Free Trial

Iradimed (IRMD) Earnings Date, Estimates & Call Transcripts

Iradimed logo
$52.38 -0.48 (-0.90%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Iradimed Latest Earnings Summary

Upcoming Q1
Earnings Date
May. 1Before Market OpensEstimated
Actual EPS
(Feb. 13)
$0.40 Missed By -$0.05
Consensus EPS
(Feb. 13)
$0.45

Iradimed announced Q4 2024 earnings on February 13, 2025, reporting an EPS of $0.40, which missed analysts' consensus estimates of $0.45 by $0.05. Quarterly revenue was reported to be $19.39 million, above analyst estimates of $19.09 million. With a trailing EPS of $1.50 and a P/E Ratio of 34.93, Iradimed's earnings are expected to grow 20.48% next year, from $1.66 to $2.00 per share.

IRMD Upcoming Earnings

Iradimed's next earnings date is estimated for Thursday, May 1, 2025, based off prior year's reporting schedules.

Get Iradimed Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

IRMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IRMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.
Remove Ads

Iradimed Analyst EPS Estimates

Current Year EPS Consensus Estimate:$1.66 EPS
Next Year EPS Consensus Estimate: $2.00 EPS
Remove Ads

Iradimed Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/1/2025
(Estimated)
-------
2/13/2025Q4 2024$0.45$0.40 -$0.05$0.40$19.09M$19.39M
8/1/2024Q2 2024$0.33$0.38+$0.05$0.38$17.70M$17.93M
5/2/2024Q1 2024$0.31$0.32+$0.01$0.32$17.26M$17.60M
2/8/2024Q4 2023$0.37$0.36 -$0.01$0.36-$17.45M
11/3/2023Q3 2023$0.34$0.40+$0.06$0.40$16.21M$16.51M
8/3/2023Q2 2023$0.28$0.33+$0.05$0.33$15.70M$16.13M
5/4/2023Q1 2023$0.25$0.27+$0.02$0.27$14.76M$15.48M

Iradimed Earnings - Frequently Asked Questions

Iradimed has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 1st, 2025 based off last year's report dates. Learn more on IRMD's earnings history.

Iradimed issued an update on its FY 2025 earnings guidance on Thursday, February, 13th. The company provided EPS guidance of 1.710-1.810 for the period, compared to the consensus estimate of 1.750. The company issued revenue guidance of $78.0 million-$82.0 million, compared to the consensus revenue estimate of $80.7 million.

In the previous quarter, Iradimed (NASDAQ:IRMD) missed the analysts' consensus estimate of $0.45 by $0.05 with a reported earnings per share (EPS) of $0.40. Learn more on analysts' earnings estimate vs. IRMD's actual earnings.

The conference call for Iradimed's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Iradimed's latest earnings report can be read online.
Read Transcript

Iradimed (NASDAQ:IRMD) has a recorded annual revenue of $73.24 million.

Iradimed (NASDAQ:IRMD) has a recorded net income of $19.23 million. IRMD has generated $1.50 earnings per share over the last four quarters.

Iradimed (NASDAQ:IRMD) has a trailing price-to-earnings ratio of 35.24 and a forward price-to-earnings ratio of 31.84.

Iradimed's earnings are expected to grow from $1.66 per share to $2.00 per share in the next year, which is a 20.48% increase.

More Earnings Resources from MarketBeat

Remove Ads


This page (NASDAQ:IRMD) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners